A pilot study of recombinant human interleukin-4 therapy of myelofibrosis.
Twelve patients with myelofibrosis were treated with recombinant human interleukin-4 (IL-4) administered subcutaneously thrice weekly. Dosage ranged from 1 microg/kg to 4 microg/kg. Median patient age was 65 years (range 36-74). Five patients had transient minor responses, and 5 patients had progressive disease. One patient had a transient minor response, rapidly followed by progressive disease. One patient suffered angioneurotic edema with first injection. Other significant toxicities included fever, flu-like symptoms, peripheral edema, and ascites. IL-4 at this schedule was toxic and had no significant activity in myelofibrosis.
Giles
F J
FJ
Department of Leukemia, University of Texas-MD Anderson Cancer Center, Houston 77030, USA. fgiles@mdanderson.org
Keating
A R
AR
Kurzrock
R
R
Talpaz
M
M
D000328:Adult; D000368:Aged; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D015847:Interleukin-4 / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; D015847:Interleukin-4